Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia
Conditions
Brief summary
This pilot phase I trial studies how well CPI-613 (6,8-bis\[benzylthio\]octanoic acid), cytarabine, and mitoxantrone hydrochloride work in treating patients with acute myeloid leukemia or granulocytic sarcoma (a malignant, green-colored tumor of myeloid cells \[a type of immature white blood cell\]) that has returned (relapsed) or that does not respond to treatment (refractory). 6,8-bis(benzylthio)octanoic acid is thought to kill cancer cells by turning off their mitochondria. Mitochondria are used by cancer cells to produce energy and are the building blocks needed to make more cancer cells. By shutting off these mitochondria, 6,8-bis(benzylthio)octanoic acid deprives the cancer cells of energy and other supplies that they need to survive and grow in the body. Drugs used in chemotherapy, such as cytarabine and mitoxantrone hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving 6,8-bis(benzylthio)octanoic acid together with cytarabine and mitoxantrone hydrochloride may kill more cancer cells.
Detailed description
PRIMARY OBJECTIVES: I. To determine the feasibility of CPI-613 when administered with high dose cytarabine, and mitoxantrone (mitoxantrone hydrochloride) in all three phases of salvage therapy (induction, consolidation and maintenance). SECONDARY OBJECTIVES: I. To observe the response rate (complete remission \[CR\], and CR with incomplete recovery \[CRi\]) of CPI-613 in combination with high dose cytarabine and mitoxantrone. II. To observe the overall survival of patients treated with CPI-613 in combination with high dose cytarabine and mitoxantrone in induction, consolidation and maintenance. III. To monitor toxicities experienced by patients treated with CPI-613 in combination with high dose cytarabine and mitoxantrone in induction, consolidation and maintenance. OUTLINE: SALVAGE INDUCTION COURSE 1: Patients receive 6,8-bis(benzylthio)octanoic acid intravenously (IV) over 2 hours on days 1-5, cytarabine IV over 3 hours every 12 hours starting on day 3 for 5 doses, and mitoxantrone hydrochloride IV over 15 minutes after the first, third, and fifth doses of cytarabine. SALVAGE INDUCTION COURSE 2 (OPTIONAL, AT DISCRETION OF TREATING PHYSICIAN): Patients receive 6,8-bis(benzylthio)octanoic acid, cytarabine, and mitoxantrone hydrochloride as in course 1 or an abbreviated second course at the discretion of the treating physician. In the abbreviated course, patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-3, cytarabine IV over 3 hours every 12 hours starting on day 2 for 3 doses, and mitoxantrone hydrochloride IV over 15 minutes after the first and third cytarabine doses. SALVAGE CONSOLIDATION: Patients achieving response receive up to 2 courses of the abbreviated course of 6,8-bis(benzylthio)octanoic acid, high dose cytarabine, and mitoxantrone hydrochloride. Patients achieving response may undergo stem cell transplant at the discretion of the treating physician. Patients may proceed to maintenance after 1, 2 or no courses of consolidation at the discretion of the treating physician. MAINTENANCE THERAPY: Patients achieving response receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically.
Interventions
Given IV
DRUGCytarabine
Given IV
PROCEDUREHematopoietic Cell Transplantation
Undergo stem cell transplant
DRUGMitoxantrone Hydrochloride
Given IV
Sponsors
National Cancer Institute (NCI)
Wake Forest University Health Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically or cytologically documented relapsed and/or refractory acute myeloid leukemia or granulocytic sarcoma * Eastern Cooperative Oncology Group (ECOG) performance status of =\< 3 * Expected survival \> 3 months * Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device \[IUD\], oral contraceptive or double barrier device), and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation * Fertile men must practice effective contraceptive methods during the study period, unless documentation of infertility exists * Mentally competent, ability to understand and willingness to sign the informed consent form * No radiotherapy, treatment with cytotoxic agents (except CPI-613), treatment with biologic agents or any anti-cancer therapy within the 2 weeks prior to treatment with CPI-613; hydroxyurea and oral tyrosine kinase inhibitors being used without grade =\< 2 toxicity can be taken until day 1 of therapy; patients must have fully recovered from the acute, non-hematological, non-infectious toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment); patients with persisting, non-hematologic, non-infectious toxicities from prior treatment =\< grade 2 are eligible, but must be documented as such * Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) =\< 3 x upper normal limit (UNL), alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) =\< 3 x UNL (=\< 5 x upper limit of normal \[ULN\] if liver metastases present) * Bilirubin =\< 1.5 x UNL * Serum creatinine =\< 1.5 mg/dL or 133 umol/L * International normalized ratio or INR must be \< 1.5 * Left ventricular ejection fraction (by transthoracic echocardiography \[TTE\], multigated acquisition scan \[MUGA\] or cardiac magnetic resonance imaging \[MRI\]) sufficient to safely administer mitoxantrone as determined by the treating physician
Exclusion criteria
* Serious medical illness, such as significant cardiac disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, pericardial disease or New York Heart Association class III or IV), or severe debilitating pulmonary disease, that would potentially increase patients' risk for toxicity * Patients with active central nervous system (CNS) or epidural tumor * Any active uncontrolled bleeding, and any patients with a bleeding diathesis (e.g., active peptic ulcer disease) * Pregnant women, or women of child-bearing potential not using reliable means of contraception * Lactating females * Fertile men unwilling to practice contraceptive methods during the study period * Life expectancy less than 3 months * Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients * Unwilling or unable to follow protocol requirements * Patients with large and recurrent pleural or peritoneal effusions requiring frequent drainage (e.g. weekly); patients with any amount of clinically significant pericardial effusion * Active heart disease including myocardial infarction within previous 6 months, symptomatic coronary artery disease, uncontrolled arrhythmias, or symptomatic congestive heart failure * Evidence of ongoing, uncontrolled infection * Patients with known human immunodeficiency virus (HIV) infection * Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication within the past 2 weeks prior to initiation of CPI-613 treatment (the use of Hydrea is allowed) * Patients who have received immunotherapy of any type within the past 4 weeks prior to initiation of CPI-613 treatment * Requirement for immediate palliative treatment of any kind including surgery * Patients that have received a chemotherapy regimen with stem cell support in the previous 6 months * A history of additional risk factors for torsade de pointes (e.g., clinically significant heart failure, hypokalemia, family history of long QT syndrome)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of Administering CPI-613 in Combination With High Dose Cytarabine and Mitoxantrone During Induction, Consolidation and Maintenance Therapies, Defined as Percentage of Patients Eligible for Maintenance Therapy Who Complete at Least 3 Courses | Up to 12 weeks of maintenance therapy | Feasibility is determined by the percentage of patients eligible for maintenance therapy who complete at least 3 cycles, if ≥50% of eligible patients complete 3 cycles of maintenance therapy we will consider this regimen feasible for future study. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Up to 6 months | The frequency of toxicities experienced by the participants will be presented by type and grade in an effort to monitor and report safety of the treatment. Showing grade 2 and greater event and the highest grade of each type per participant so that a participant is only evaluated once per toxicity type. Reporting events where at least 10% (n=5) of study participants reported a grade 2 or greater event. |
| Overall Survival | Time from enrollment on trial to death from any cause, assessed up to 30 months after completion of therapy | Will use Kaplan-Meier estimation to analyze overall survival. |
| Response Rate (CR and CRi), Assessed by Standard Criteria for AML | Up to 3 years | Confidence intervals will be calculated around the estimates of the response rate (CR and CRi). Assuming a response rate of 0.5, with 50 participants, 95 percent confidence intervals can be created with a 0.14 margin of error (0.36, 0.64). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Early Mortality (Death Within 60 Days of Beginning of Treatment) | Up to 60 days | Early mortality (death within 60 days of beginning of treatment). |
| Complete Response | Up to 3 years | Complete response rates |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 1500 1500 mg/m2 devimistat | 21 |
| 2000 2000 mg/m2 devimistat | 20 |
| 2500 2500 mg/m2 devimistat | 7 |
| Total | 48 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Lack of Efficacy | 15 | 14 | 3 |
| Overall Study | Lost to Follow-up | 0 | 0 | 2 |
| Overall Study | Physician Decision | 1 | 3 | 0 |
| Overall Study | Went to Transplant | 5 | 3 | 2 |
Baseline characteristics
| Characteristic | 1500 | 2000 | 2500 | Total |
|---|---|---|---|---|
| Age, Continuous | 61 years | 65.5 years | 64 years | 64 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants | 3 Participants | 1 Participants | 7 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) White | 18 Participants | 16 Participants | 6 Participants | 40 Participants |
| Sex: Female, Male Female | 9 Participants | 8 Participants | 3 Participants | 20 Participants |
| Sex: Female, Male Male | 12 Participants | 12 Participants | 4 Participants | 28 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 6 / 21 | 6 / 20 | 1 / 7 |
| other Total, other adverse events | 21 / 21 | 20 / 20 | 7 / 7 |
| serious Total, serious adverse events | 21 / 21 | 16 / 20 | 4 / 7 |
Outcome results
Primary
Feasibility of Administering CPI-613 in Combination With High Dose Cytarabine and Mitoxantrone During Induction, Consolidation and Maintenance Therapies, Defined as Percentage of Patients Eligible for Maintenance Therapy Who Complete at Least 3 Courses
Feasibility is determined by the percentage of patients eligible for maintenance therapy who complete at least 3 cycles, if ≥50% of eligible patients complete 3 cycles of maintenance therapy we will consider this regimen feasible for future study.
Time frame: Up to 12 weeks of maintenance therapy
Population: None of the 9 participants in the 1500 mg arm and the 7 participants in the 2000 mg arm started maintenance, only 2 out of the 5 participants in the 2500 mg arm started maintenance. None of participants completed three cycles of maintenance.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 1500 | Feasibility of Administering CPI-613 in Combination With High Dose Cytarabine and Mitoxantrone During Induction, Consolidation and Maintenance Therapies, Defined as Percentage of Patients Eligible for Maintenance Therapy Who Complete at Least 3 Courses | Started maintenance therapy | 0 Participants |
| 1500 | Feasibility of Administering CPI-613 in Combination With High Dose Cytarabine and Mitoxantrone During Induction, Consolidation and Maintenance Therapies, Defined as Percentage of Patients Eligible for Maintenance Therapy Who Complete at Least 3 Courses | Completed 3 cycles of maintenance therapy | 0 Participants |
| 2000 | Feasibility of Administering CPI-613 in Combination With High Dose Cytarabine and Mitoxantrone During Induction, Consolidation and Maintenance Therapies, Defined as Percentage of Patients Eligible for Maintenance Therapy Who Complete at Least 3 Courses | Started maintenance therapy | 0 Participants |
| 2000 | Feasibility of Administering CPI-613 in Combination With High Dose Cytarabine and Mitoxantrone During Induction, Consolidation and Maintenance Therapies, Defined as Percentage of Patients Eligible for Maintenance Therapy Who Complete at Least 3 Courses | Completed 3 cycles of maintenance therapy | 0 Participants |
| 2500 | Feasibility of Administering CPI-613 in Combination With High Dose Cytarabine and Mitoxantrone During Induction, Consolidation and Maintenance Therapies, Defined as Percentage of Patients Eligible for Maintenance Therapy Who Complete at Least 3 Courses | Started maintenance therapy | 2 Participants |
| 2500 | Feasibility of Administering CPI-613 in Combination With High Dose Cytarabine and Mitoxantrone During Induction, Consolidation and Maintenance Therapies, Defined as Percentage of Patients Eligible for Maintenance Therapy Who Complete at Least 3 Courses | Completed 3 cycles of maintenance therapy | 0 Participants |
Secondary
Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0
The frequency of toxicities experienced by the participants will be presented by type and grade in an effort to monitor and report safety of the treatment. Showing grade 2 and greater event and the highest grade of each type per participant so that a participant is only evaluated once per toxicity type. Reporting events where at least 10% (n=5) of study participants reported a grade 2 or greater event.
Time frame: Up to 6 months
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lung infection | Not observed or Grade 1 | 15 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Febrile neutropenia | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Somnolence | Not observed or Grade 1 | 18 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Febrile neutropenia | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Cardiac troponin I increased | Grade 3 | 3 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory failure | Not observed or Grade 1 | 16 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Abdominal pain | Not observed or Grade 1 | 18 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Febrile neutropenia | Grade 3 | 6 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sore throat | Grade 2 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lung infection | Grade 5 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Febrile neutropenia | Grade 2 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sore throat | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory, thoracic and mediastinal disorders - Other | Grade 2 | 4 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fatigue | Not observed or Grade 1 | 11 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sore throat | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Headache | Not observed or Grade 1 | 16 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fatigue | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sore throat | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lung infection | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fatigue | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sore throat | Not observed or Grade 1 | 19 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory, thoracic and mediastinal disorders - Other | Grade 3 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fatigue | Grade 3 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Vomiting | Grade 2 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Non-cardiac chest pain | Grade 3 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fatigue | Grade 2 | 8 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Epistaxis | Not observed or Grade 1 | 18 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Vomiting | Grade 3 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Cardiac troponin I increased | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lung infection | Grade 3 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory, thoracic and mediastinal disorders - Other | Grade 4 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Epistaxis | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Cardiac troponin I increased | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Epistaxis | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Vomiting | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Activated partial thromboplastin time prolonged | Grade 2 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lung infection | Grade 2 | 4 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Epistaxis | Grade 3 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Cardiac troponin I increased | Not observed or Grade 1 | 18 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Insomnia | Not observed or Grade 1 | 17 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Epistaxis | Grade 2 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Catheter related infection | Grade 2 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Electrocardiogram QT corrected interval prolonged | Not observed or Grade 1 | 19 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysphagia | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Vomiting | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Electrocardiogram QT corrected interval prolonged | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain | Not observed or Grade 1 | 16 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Electrocardiogram QT corrected interval prolonged | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Catheter related infection | Grade 3 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Activated partial thromboplastin time prolonged | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Vomiting | Not observed or Grade 1 | 19 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Non-cardiac chest pain | Grade 2 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Electrocardiogram QT corrected interval prolonged | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Electrocardiogram QT corrected interval prolonged | Grade 2 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Catheter related infection | Grade 4 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Insomnia | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight gain | Grade 2 | 4 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Activated partial thromboplastin time prolonged | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Ejection fraction decreased | Not observed or Grade 1 | 18 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight gain | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Ejection fraction decreased | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Insomnia | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Ejection fraction decreased | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight gain | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Catheter related infection | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Activated partial thromboplastin time prolonged | Not observed or Grade 1 | 17 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Ejection fraction decreased | Grade 3 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Activated partial thromboplastin time prolonged | Grade 3 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Catheter related infection | Not observed or Grade 1 | 18 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Edema limbs | Not observed or Grade 1 | 17 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight gain | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Insomnia | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Acute kidney injury | Grade 2 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Edema limbs | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight gain | Not observed or Grade 1 | 17 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain | Grade 2 | 4 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Edema limbs | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight loss | Grade 2 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Insomnia | Grade 2 | 4 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Edema limbs | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight loss | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Acute kidney injury | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Edema limbs | Grade 2 | 4 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight loss | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neutrophil count decreased | Not observed or Grade 1 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dyspnea | Not observed or Grade 1 | 15 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dyspnea | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chills | Grade 2 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Infections and infestations - Other | Not observed or Grade 1 | 16 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dyspnea | Grade 4 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chills | Grade 3 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Acute kidney injury | Grade 4 | 3 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dyspnea | Grade 3 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chills | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neutrophil count decreased | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dyspnea | Grade 2 | 3 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chills | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Infections and infestations - Other | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chills | Not observed or Grade 1 | 18 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Acute kidney injury | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysphagia | Not observed or Grade 1 | 14 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chronic kidney disease | Grade 2 | 3 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysphagia | Grade 3 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysphagia | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chronic kidney disease | Grade 3 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Infections and infestations - Other | Grade 4 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | White blood cell decreased | Not observed or Grade 1 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chronic kidney disease | Grade 4 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Acute kidney injury | Not observed or Grade 1 | 16 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | White blood cell decreased | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoxia | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | White blood cell decreased | Grade 4 | 21 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chronic kidney disease | Not observed or Grade 1 | 15 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoxia | Not observed or Grade 1 | 18 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | White blood cell decreased | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Confusion | Grade 2 | 4 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Agitation | Grade 2 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | White blood cell decreased | Grade 2 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Confusion | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain in extremity | Grade 2 | 4 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight loss | Not observed or Grade 1 | 21 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Confusion | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoxia | Grade 4 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight loss | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Confusion | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Agitation | Grade 3 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysphagia | Grade 2 | 5 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Confusion | Not observed or Grade 1 | 17 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Infections and infestations - Other | Grade 2 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysgeusia | Not observed or Grade 1 | 20 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Creatinine increased | Grade 2 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoxia | Grade 3 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysgeusia | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Creatinine increased | Grade 3 | 3 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Agitation | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysgeusia | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Creatinine increased | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neutrophil count decreased | Grade 4 | 21 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysgeusia | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Creatinine increased | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoxia | Grade 2 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysgeusia | Grade 2 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Creatinine increased | Not observed or Grade 1 | 16 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Agitation | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Disseminated intravascular coagulation | Not observed or Grade 1 | 6 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dehydration | Grade 2 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain in extremity | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Disseminated intravascular coagulation | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dehydration | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypotension | Not observed or Grade 1 | 17 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Disseminated intravascular coagulation | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dehydration | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Agitation | Not observed or Grade 1 | 17 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Disseminated intravascular coagulation | Grade 3 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dehydration | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neutrophil count decreased | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Disseminated intravascular coagulation | Grade 2 | 14 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dehydration | Not observed or Grade 1 | 20 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypotension | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Diarrhea | Not observed or Grade 1 | 11 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Delirium | Grade 2 | 4 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alanine aminotransferase increased | Grade 2 | 3 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Diarrhea | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Delirium | Grade 3 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain in extremity | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Diarrhea | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Delirium | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypotension | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Diarrhea | Grade 3 | 5 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Delirium | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alanine aminotransferase increased | Grade 3 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Diarrhea | Grade 2 | 5 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Delirium | Not observed or Grade 1 | 15 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Back pain | Not observed or Grade 1 | 19 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Depression | Not observed or Grade 1 | 19 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Depression | Grade 2 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypotension | Grade 3 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Depression | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Depression | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Depression | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neutrophil count decreased | Grade 2 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypotension | Grade 2 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alanine aminotransferase increased | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain in extremity | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypophosphatemia | Not observed or Grade 1 | 8 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alanine aminotransferase increased | Not observed or Grade 1 | 17 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Infections and infestations - Other | Grade 3 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypophosphatemia | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alkalosis | Grade 2 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neck pain | Not observed or Grade 1 | 18 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypophosphatemia | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alkalosis | Grade 3 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain in extremity | Not observed or Grade 1 | 17 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypophosphatemia | Grade 3 | 6 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alkalosis | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Oral pain | Not observed or Grade 1 | 21 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypophosphatemia | Grade 2 | 7 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alkalosis | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neck pain | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyponatremia | Not observed or Grade 1 | 16 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alkalosis | Not observed or Grade 1 | 19 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Platelet count decreased | Grade 2 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyponatremia | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anemia | Grade 2 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood and lymphatic system disorders - Other | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anemia | Grade 3 | 19 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neck pain | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyponatremia | Grade 4 | 3 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anemia | Grade 4 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Platelet count decreased | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyponatremia | Grade 3 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anemia | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood bilirubin increased | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyponatremia | Grade 2 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anemia | Not observed or Grade 1 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neck pain | Grade 3 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypomagnesemia | Not observed or Grade 1 | 17 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anorexia | Grade 2 | 9 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Platelet count decreased | Grade 4 | 21 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypomagnesemia | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anorexia | Grade 3 | 4 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Oral pain | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypomagnesemia | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anorexia | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neck pain | Grade 2 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypomagnesemia | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anorexia | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Platelet count decreased | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypomagnesemia | Grade 2 | 4 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anorexia | Not observed or Grade 1 | 8 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Oral pain | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypokalemia | Not observed or Grade 1 | 12 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anxiety | Grade 2 | 5 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Nausea | Not observed or Grade 1 | 15 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypokalemia | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anxiety | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Platelet count decreased | Not observed or Grade 1 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypokalemia | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anxiety | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypokalemia | Grade 3 | 7 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anxiety | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Nausea | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypokalemia | Grade 2 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory, thoracic and mediastinal disorders - Other | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Proteinuria | Grade 2 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anxiety | Not observed or Grade 1 | 16 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypocalcemia | Not observed or Grade 1 | 15 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory, thoracic and mediastinal disorders - Other | Not observed or Grade 1 | 15 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Skin and subcutaneous tissue disorders - Other | Grade 2 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypocalcemia | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Aspartate aminotransferase increased | Grade 2 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Nausea | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypocalcemia | Grade 4 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Aspartate aminotransferase increased | Grade 3 | 3 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Proteinuria | Grade 3 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypocalcemia | Grade 3 | 3 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinus tachycardia | Grade 2 | 4 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Oral pain | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypocalcemia | Grade 2 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Nausea | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoalbuminemia | Not observed or Grade 1 | 4 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Proteinuria | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoalbuminemia | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Aspartate aminotransferase increased | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Abdominal pain | Grade 2 | 3 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoalbuminemia | Grade 4 | 3 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Aspartate aminotransferase increased | Not observed or Grade 1 | 16 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Nausea | Grade 2 | 6 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoalbuminemia | Grade 3 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Back pain | Grade 2 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Proteinuria | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoalbuminemia | Grade 2 | 13 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Back pain | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chronic kidney disease | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypertension | Not observed or Grade 1 | 13 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Back pain | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Mucositis oral | Not observed or Grade 1 | 20 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypertension | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Back pain | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypertension | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinus tachycardia | Grade 3 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Proteinuria | Not observed or Grade 1 | 18 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypertension | Grade 3 | 5 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinus tachycardia | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Oral pain | Grade 2 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Mucositis oral | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypertension | Grade 2 | 3 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyperglycemia | Not observed or Grade 1 | 10 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood and lymphatic system disorders - Other | Grade 2 | 4 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pulmonary edema | Grade 2 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinus tachycardia | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Abdominal pain | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyperglycemia | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyperglycemia | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinus tachycardia | Not observed or Grade 1 | 16 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood and lymphatic system disorders - Other | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Mucositis oral | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyperglycemia | Grade 3 | 5 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinusitis | Grade 2 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pulmonary edema | Grade 3 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyperglycemia | Grade 2 | 6 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Ejection fraction decreased | Grade 2 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Headache | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Mucositis oral | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Headache | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood and lymphatic system disorders - Other | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinusitis | Grade 3 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pulmonary edema | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Non-cardiac chest pain | Not observed or Grade 1 | 18 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Headache | Grade 3 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinusitis | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Mucositis oral | Grade 2 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Headache | Grade 2 | 3 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood and lymphatic system disorders - Other | Not observed or Grade 1 | 17 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pulmonary edema | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Generalized muscle weakness | Not observed or Grade 1 | 15 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinusitis | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Abdominal pain | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Generalized muscle weakness | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinusitis | Not observed or Grade 1 | 18 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lymphocyte count decreased | Not observed or Grade 1 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Generalized muscle weakness | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pulmonary edema | Not observed or Grade 1 | 18 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Generalized muscle weakness | Grade 3 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Generalized muscle weakness | Grade 2 | 4 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Skin and subcutaneous tissue disorders - Other | Grade 3 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood bilirubin increased | Grade 2 | 5 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lymphocyte count decreased | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Gastrointestinal disorders - Other | Not observed or Grade 1 | 20 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Skin and subcutaneous tissue disorders - Other | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory failure | Grade 2 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Gastrointestinal disorders - Other | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Skin and subcutaneous tissue disorders - Other | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood bilirubin increased | Grade 3 | 2 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Non-cardiac chest pain | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lymphocyte count decreased | Grade 4 | 21 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Gastrointestinal disorders - Other | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Gastrointestinal disorders - Other | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Skin and subcutaneous tissue disorders - Other | Not observed or Grade 1 | 19 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory failure | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Gastrointestinal disorders - Other | Grade 2 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Somnolence | Grade 2 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Abdominal pain | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lymphocyte count decreased | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fever | Not observed or Grade 1 | 9 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fever | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood bilirubin increased | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Somnolence | Grade 3 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory failure | Grade 4 | 5 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fever | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain | Grade 3 | 1 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood bilirubin increased | Not observed or Grade 1 | 14 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lymphocyte count decreased | Grade 2 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fever | Grade 3 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Cardiac troponin I increased | Grade 2 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fever | Grade 2 | 12 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Somnolence | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory failure | Grade 5 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Non-cardiac chest pain | Grade 4 | 0 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Febrile neutropenia | Not observed or Grade 1 | 15 Participants |
| 1500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Somnolence | Grade 5 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Electrocardiogram QT corrected interval prolonged | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Back pain | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypophosphatemia | Grade 2 | 8 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Infections and infestations - Other | Grade 2 | 3 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Nausea | Grade 3 | 5 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Nausea | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain in extremity | Grade 3 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Abdominal pain | Grade 2 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Abdominal pain | Grade 3 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Abdominal pain | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Abdominal pain | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Abdominal pain | Not observed or Grade 1 | 18 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Activated partial thromboplastin time prolonged | Grade 2 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Activated partial thromboplastin time prolonged | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysphagia | Grade 3 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain in extremity | Grade 2 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain in extremity | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain in extremity | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain in extremity | Not observed or Grade 1 | 19 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Platelet count decreased | Grade 2 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Platelet count decreased | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Platelet count decreased | Grade 4 | 20 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Platelet count decreased | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Platelet count decreased | Not observed or Grade 1 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Proteinuria | Grade 2 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Proteinuria | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Proteinuria | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Proteinuria | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Proteinuria | Not observed or Grade 1 | 19 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pulmonary edema | Grade 2 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pulmonary edema | Grade 3 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pulmonary edema | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pulmonary edema | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pulmonary edema | Not observed or Grade 1 | 18 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory failure | Grade 2 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory failure | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory failure | Grade 4 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory failure | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory failure | Not observed or Grade 1 | 18 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory, thoracic and mediastinal disorders - Other | Grade 2 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory, thoracic and mediastinal disorders - Other | Grade 3 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory, thoracic and mediastinal disorders - Other | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysphagia | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Activated partial thromboplastin time prolonged | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Activated partial thromboplastin time prolonged | Not observed or Grade 1 | 20 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Acute kidney injury | Grade 2 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Acute kidney injury | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Acute kidney injury | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Acute kidney injury | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Acute kidney injury | Not observed or Grade 1 | 19 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Agitation | Grade 2 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Agitation | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Agitation | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Agitation | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Agitation | Not observed or Grade 1 | 19 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alanine aminotransferase increased | Grade 2 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alanine aminotransferase increased | Grade 3 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alanine aminotransferase increased | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alanine aminotransferase increased | Not observed or Grade 1 | 17 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alkalosis | Grade 2 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alkalosis | Grade 3 | 3 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alkalosis | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alkalosis | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alkalosis | Not observed or Grade 1 | 17 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anemia | Grade 2 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anemia | Grade 3 | 19 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anemia | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anemia | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anemia | Not observed or Grade 1 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anorexia | Grade 2 | 8 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anorexia | Grade 3 | 8 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anorexia | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anorexia | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anorexia | Not observed or Grade 1 | 4 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anxiety | Grade 2 | 7 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anxiety | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anxiety | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anxiety | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory, thoracic and mediastinal disorders - Other | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anxiety | Not observed or Grade 1 | 13 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Aspartate aminotransferase increased | Grade 2 | 3 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory, thoracic and mediastinal disorders - Other | Not observed or Grade 1 | 18 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Aspartate aminotransferase increased | Grade 3 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinus tachycardia | Grade 2 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Aspartate aminotransferase increased | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Aspartate aminotransferase increased | Not observed or Grade 1 | 16 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Back pain | Grade 2 | 5 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Back pain | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Back pain | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinus tachycardia | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinus tachycardia | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Back pain | Not observed or Grade 1 | 15 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood and lymphatic system disorders - Other | Grade 2 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinus tachycardia | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinus tachycardia | Not observed or Grade 1 | 19 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinusitis | Grade 2 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood and lymphatic system disorders - Other | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood and lymphatic system disorders - Other | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinusitis | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood and lymphatic system disorders - Other | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinusitis | Grade 4 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood and lymphatic system disorders - Other | Not observed or Grade 1 | 19 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinusitis | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinusitis | Not observed or Grade 1 | 19 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Skin and subcutaneous tissue disorders - Other | Grade 2 | 3 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Skin and subcutaneous tissue disorders - Other | Grade 3 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood bilirubin increased | Grade 2 | 5 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Skin and subcutaneous tissue disorders - Other | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood bilirubin increased | Grade 3 | 5 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Skin and subcutaneous tissue disorders - Other | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Skin and subcutaneous tissue disorders - Other | Not observed or Grade 1 | 16 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Somnolence | Grade 2 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood bilirubin increased | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood bilirubin increased | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Somnolence | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood bilirubin increased | Not observed or Grade 1 | 10 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Somnolence | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Cardiac troponin I increased | Grade 2 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Somnolence | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Cardiac troponin I increased | Grade 3 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Somnolence | Not observed or Grade 1 | 19 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sore throat | Grade 2 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sore throat | Grade 3 | 3 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sore throat | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sore throat | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sore throat | Not observed or Grade 1 | 17 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Vomiting | Grade 2 | 3 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Vomiting | Grade 3 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Cardiac troponin I increased | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Cardiac troponin I increased | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Vomiting | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Cardiac troponin I increased | Not observed or Grade 1 | 18 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Catheter related infection | Grade 2 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Vomiting | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Catheter related infection | Grade 3 | 6 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Vomiting | Not observed or Grade 1 | 15 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Catheter related infection | Grade 4 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight gain | Grade 2 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight gain | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Catheter related infection | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight gain | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Catheter related infection | Not observed or Grade 1 | 13 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight gain | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight gain | Not observed or Grade 1 | 18 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight loss | Grade 2 | 9 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight loss | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight loss | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chills | Grade 2 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chills | Grade 3 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chills | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chills | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chills | Not observed or Grade 1 | 18 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chronic kidney disease | Grade 2 | 11 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chronic kidney disease | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chronic kidney disease | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chronic kidney disease | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chronic kidney disease | Not observed or Grade 1 | 9 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Confusion | Grade 2 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Confusion | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Confusion | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Confusion | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Confusion | Not observed or Grade 1 | 18 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Creatinine increased | Grade 2 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Creatinine increased | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Creatinine increased | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Creatinine increased | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Creatinine increased | Not observed or Grade 1 | 20 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dehydration | Grade 2 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dehydration | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dehydration | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dehydration | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dehydration | Not observed or Grade 1 | 19 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Delirium | Grade 2 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Delirium | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Delirium | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Delirium | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Delirium | Not observed or Grade 1 | 19 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Depression | Grade 2 | 3 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Depression | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Depression | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Depression | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Depression | Not observed or Grade 1 | 17 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Diarrhea | Grade 2 | 9 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Diarrhea | Grade 3 | 6 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Diarrhea | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Diarrhea | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Diarrhea | Not observed or Grade 1 | 5 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Disseminated intravascular coagulation | Grade 2 | 18 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Disseminated intravascular coagulation | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Disseminated intravascular coagulation | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Disseminated intravascular coagulation | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Disseminated intravascular coagulation | Not observed or Grade 1 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysgeusia | Grade 2 | 4 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysgeusia | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysgeusia | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysgeusia | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysgeusia | Not observed or Grade 1 | 16 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysphagia | Grade 2 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight loss | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight loss | Not observed or Grade 1 | 11 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | White blood cell decreased | Grade 2 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | White blood cell decreased | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | White blood cell decreased | Grade 4 | 19 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | White blood cell decreased | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | White blood cell decreased | Not observed or Grade 1 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysphagia | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysphagia | Not observed or Grade 1 | 18 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dyspnea | Grade 2 | 6 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dyspnea | Grade 3 | 4 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dyspnea | Grade 4 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dyspnea | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dyspnea | Not observed or Grade 1 | 9 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Edema limbs | Grade 2 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Edema limbs | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Edema limbs | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Edema limbs | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Edema limbs | Not observed or Grade 1 | 18 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Ejection fraction decreased | Grade 2 | 5 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Ejection fraction decreased | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Ejection fraction decreased | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Ejection fraction decreased | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Ejection fraction decreased | Not observed or Grade 1 | 15 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Electrocardiogram QT corrected interval prolonged | Grade 2 | 4 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Electrocardiogram QT corrected interval prolonged | Grade 3 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Electrocardiogram QT corrected interval prolonged | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Activated partial thromboplastin time prolonged | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Electrocardiogram QT corrected interval prolonged | Not observed or Grade 1 | 15 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Epistaxis | Grade 2 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Epistaxis | Grade 3 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Epistaxis | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Epistaxis | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Epistaxis | Not observed or Grade 1 | 18 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fatigue | Grade 2 | 10 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fatigue | Grade 3 | 4 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fatigue | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fatigue | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fatigue | Not observed or Grade 1 | 6 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Febrile neutropenia | Grade 2 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Febrile neutropenia | Grade 3 | 13 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Febrile neutropenia | Grade 4 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Febrile neutropenia | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Febrile neutropenia | Not observed or Grade 1 | 6 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fever | Grade 2 | 9 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fever | Grade 3 | 3 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fever | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fever | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fever | Not observed or Grade 1 | 8 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Gastrointestinal disorders - Other | Grade 2 | 3 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Gastrointestinal disorders - Other | Grade 3 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Gastrointestinal disorders - Other | Grade 4 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Gastrointestinal disorders - Other | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Gastrointestinal disorders - Other | Not observed or Grade 1 | 14 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Generalized muscle weakness | Grade 2 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Generalized muscle weakness | Grade 3 | 5 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Generalized muscle weakness | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Generalized muscle weakness | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Generalized muscle weakness | Not observed or Grade 1 | 13 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Headache | Grade 2 | 4 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Headache | Grade 3 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Headache | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Headache | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Headache | Not observed or Grade 1 | 14 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyperglycemia | Grade 2 | 6 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyperglycemia | Grade 3 | 3 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyperglycemia | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyperglycemia | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyperglycemia | Not observed or Grade 1 | 11 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypertension | Grade 2 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypertension | Grade 3 | 3 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypertension | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypertension | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypertension | Not observed or Grade 1 | 15 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoalbuminemia | Grade 2 | 16 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoalbuminemia | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoalbuminemia | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoalbuminemia | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoalbuminemia | Not observed or Grade 1 | 4 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypocalcemia | Grade 2 | 9 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypocalcemia | Grade 3 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypocalcemia | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypocalcemia | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypocalcemia | Not observed or Grade 1 | 10 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypokalemia | Grade 2 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypokalemia | Grade 3 | 8 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypokalemia | Grade 4 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypokalemia | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypokalemia | Not observed or Grade 1 | 9 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypomagnesemia | Grade 2 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypomagnesemia | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypomagnesemia | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypomagnesemia | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypomagnesemia | Not observed or Grade 1 | 19 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyponatremia | Grade 2 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyponatremia | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyponatremia | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyponatremia | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyponatremia | Not observed or Grade 1 | 20 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypophosphatemia | Grade 3 | 6 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypophosphatemia | Grade 4 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypophosphatemia | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypophosphatemia | Not observed or Grade 1 | 4 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypotension | Grade 2 | 3 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypotension | Grade 3 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypotension | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypotension | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypotension | Not observed or Grade 1 | 15 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoxia | Grade 2 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoxia | Grade 3 | 3 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoxia | Grade 4 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoxia | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoxia | Not observed or Grade 1 | 15 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Infections and infestations - Other | Grade 3 | 5 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Infections and infestations - Other | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Infections and infestations - Other | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Infections and infestations - Other | Not observed or Grade 1 | 12 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Insomnia | Grade 2 | 4 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Insomnia | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Insomnia | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Insomnia | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Insomnia | Not observed or Grade 1 | 16 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lung infection | Grade 2 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lung infection | Grade 3 | 9 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lung infection | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lung infection | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lung infection | Not observed or Grade 1 | 9 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lymphocyte count decreased | Grade 2 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lymphocyte count decreased | Grade 3 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lymphocyte count decreased | Grade 4 | 19 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lymphocyte count decreased | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lymphocyte count decreased | Not observed or Grade 1 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Mucositis oral | Grade 2 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Mucositis oral | Grade 3 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Mucositis oral | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Mucositis oral | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Mucositis oral | Not observed or Grade 1 | 16 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Nausea | Grade 2 | 8 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Nausea | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Nausea | Not observed or Grade 1 | 7 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neck pain | Grade 2 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neck pain | Grade 3 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neck pain | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neck pain | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neck pain | Not observed or Grade 1 | 19 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neutrophil count decreased | Grade 2 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neutrophil count decreased | Grade 3 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neutrophil count decreased | Grade 4 | 19 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neutrophil count decreased | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neutrophil count decreased | Not observed or Grade 1 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Non-cardiac chest pain | Grade 2 | 2 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Non-cardiac chest pain | Grade 3 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Non-cardiac chest pain | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Non-cardiac chest pain | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Non-cardiac chest pain | Not observed or Grade 1 | 17 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Oral pain | Grade 2 | 3 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Oral pain | Grade 3 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Oral pain | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Oral pain | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Oral pain | Not observed or Grade 1 | 16 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain | Grade 2 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain | Grade 3 | 1 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain | Grade 4 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain | Grade 5 | 0 Participants |
| 2000 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain | Not observed or Grade 1 | 18 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lung infection | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Febrile neutropenia | Not observed or Grade 1 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Somnolence | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory failure | Not observed or Grade 1 | 7 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fever | Grade 2 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood bilirubin increased | Not observed or Grade 1 | 5 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoxia | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fever | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood bilirubin increased | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lung infection | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fever | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Somnolence | Grade 2 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory failure | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fever | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood bilirubin increased | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Non-cardiac chest pain | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fever | Not observed or Grade 1 | 4 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Skin and subcutaneous tissue disorders - Other | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lung infection | Not observed or Grade 1 | 5 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Gastrointestinal disorders - Other | Grade 2 | 5 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Skin and subcutaneous tissue disorders - Other | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory failure | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Gastrointestinal disorders - Other | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood bilirubin increased | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Abdominal pain | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Gastrointestinal disorders - Other | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Skin and subcutaneous tissue disorders - Other | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lymphocyte count decreased | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Gastrointestinal disorders - Other | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood bilirubin increased | Grade 2 | 2 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory failure | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Gastrointestinal disorders - Other | Not observed or Grade 1 | 2 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Skin and subcutaneous tissue disorders - Other | Grade 2 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain | Not observed or Grade 1 | 2 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Generalized muscle weakness | Grade 2 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood and lymphatic system disorders - Other | Not observed or Grade 1 | 7 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lymphocyte count decreased | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Generalized muscle weakness | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinusitis | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory failure | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Generalized muscle weakness | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinusitis | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Non-cardiac chest pain | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Generalized muscle weakness | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinusitis | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lymphocyte count decreased | Grade 4 | 7 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Generalized muscle weakness | Not observed or Grade 1 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood and lymphatic system disorders - Other | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pulmonary edema | Not observed or Grade 1 | 7 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Headache | Grade 2 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinusitis | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Abdominal pain | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Headache | Grade 3 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood and lymphatic system disorders - Other | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lymphocyte count decreased | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Headache | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood and lymphatic system disorders - Other | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pulmonary edema | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Headache | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Electrocardiogram QT corrected interval prolonged | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Headache | Not observed or Grade 1 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinusitis | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lymphocyte count decreased | Not observed or Grade 1 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyperglycemia | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinus tachycardia | Not observed or Grade 1 | 7 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pulmonary edema | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyperglycemia | Grade 3 | 2 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinus tachycardia | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Non-cardiac chest pain | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyperglycemia | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Blood and lymphatic system disorders - Other | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Mucositis oral | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyperglycemia | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinus tachycardia | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pulmonary edema | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyperglycemia | Not observed or Grade 1 | 5 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Back pain | Not observed or Grade 1 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Abdominal pain | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypertension | Grade 2 | 2 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinus tachycardia | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Mucositis oral | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypertension | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Back pain | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pulmonary edema | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypertension | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Back pain | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypertension | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Back pain | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Mucositis oral | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypertension | Not observed or Grade 1 | 5 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Back pain | Grade 2 | 4 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Proteinuria | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoalbuminemia | Grade 2 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Aspartate aminotransferase increased | Not observed or Grade 1 | 5 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Non-cardiac chest pain | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoalbuminemia | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Aspartate aminotransferase increased | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Mucositis oral | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoalbuminemia | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Proteinuria | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoalbuminemia | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sinus tachycardia | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Abdominal pain | Grade 2 | 5 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoalbuminemia | Not observed or Grade 1 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Aspartate aminotransferase increased | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Mucositis oral | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypocalcemia | Grade 2 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory, thoracic and mediastinal disorders - Other | Not observed or Grade 1 | 7 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Proteinuria | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypocalcemia | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Aspartate aminotransferase increased | Grade 2 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain | Grade 3 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypocalcemia | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anxiety | Not observed or Grade 1 | 2 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Proteinuria | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypocalcemia | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory, thoracic and mediastinal disorders - Other | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Nausea | Grade 3 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypocalcemia | Not observed or Grade 1 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anxiety | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Proteinuria | Grade 2 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypokalemia | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anxiety | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Oral pain | Grade 2 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypokalemia | Grade 3 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anxiety | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Nausea | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypokalemia | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anxiety | Grade 2 | 5 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Platelet count decreased | Not observed or Grade 1 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypokalemia | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anorexia | Not observed or Grade 1 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Platelet count decreased | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypokalemia | Not observed or Grade 1 | 4 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anorexia | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Skin and subcutaneous tissue disorders - Other | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypomagnesemia | Grade 2 | 2 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anorexia | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Nausea | Not observed or Grade 1 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypomagnesemia | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anorexia | Grade 3 | 2 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Platelet count decreased | Grade 4 | 7 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypomagnesemia | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anorexia | Grade 2 | 4 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Electrocardiogram QT corrected interval prolonged | Grade 2 | 4 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypomagnesemia | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anemia | Not observed or Grade 1 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neck pain | Grade 2 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypomagnesemia | Not observed or Grade 1 | 5 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anemia | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Platelet count decreased | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyponatremia | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anemia | Grade 4 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Oral pain | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyponatremia | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anemia | Grade 3 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neck pain | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyponatremia | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alkalosis | Not observed or Grade 1 | 7 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Platelet count decreased | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyponatremia | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alkalosis | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain | Grade 2 | 2 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hyponatremia | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alkalosis | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypophosphatemia | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alkalosis | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neck pain | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypophosphatemia | Grade 3 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alkalosis | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain in extremity | Not observed or Grade 1 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypophosphatemia | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alanine aminotransferase increased | Not observed or Grade 1 | 5 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Anemia | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypophosphatemia | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alanine aminotransferase increased | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neck pain | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypophosphatemia | Not observed or Grade 1 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Depression | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain in extremity | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Depression | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Depression | Grade 2 | 2 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypotension | Grade 2 | 4 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Depression | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Delirium | Not observed or Grade 1 | 7 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alanine aminotransferase increased | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Depression | Not observed or Grade 1 | 5 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Delirium | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Oral pain | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Diarrhea | Grade 2 | 2 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Delirium | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypotension | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Diarrhea | Grade 3 | 4 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Delirium | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Alanine aminotransferase increased | Grade 2 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Diarrhea | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Delirium | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neck pain | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Diarrhea | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dehydration | Not observed or Grade 1 | 4 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypotension | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Diarrhea | Not observed or Grade 1 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dehydration | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Agitation | Not observed or Grade 1 | 7 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Disseminated intravascular coagulation | Grade 2 | 7 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dehydration | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain in extremity | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Disseminated intravascular coagulation | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dehydration | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypotension | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Disseminated intravascular coagulation | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dehydration | Grade 2 | 2 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Agitation | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Disseminated intravascular coagulation | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Creatinine increased | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Nausea | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Disseminated intravascular coagulation | Not observed or Grade 1 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Creatinine increased | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypotension | Not observed or Grade 1 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysgeusia | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Creatinine increased | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Agitation | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysgeusia | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Creatinine increased | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neutrophil count decreased | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysgeusia | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Creatinine increased | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoxia | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysgeusia | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Confusion | Not observed or Grade 1 | 5 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Agitation | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysgeusia | Not observed or Grade 1 | 7 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Confusion | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain in extremity | Grade 3 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Confusion | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoxia | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight loss | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Confusion | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Agitation | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight loss | Not observed or Grade 1 | 4 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Confusion | Grade 2 | 2 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | White blood cell decreased | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chronic kidney disease | Not observed or Grade 1 | 4 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neutrophil count decreased | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | White blood cell decreased | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chronic kidney disease | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoxia | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | White blood cell decreased | Grade 4 | 7 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chronic kidney disease | Grade 4 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Acute kidney injury | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | White blood cell decreased | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chronic kidney disease | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Pain in extremity | Grade 2 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | White blood cell decreased | Not observed or Grade 1 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysphagia | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chronic kidney disease | Grade 2 | 2 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Hypoxia | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysphagia | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chills | Not observed or Grade 1 | 7 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Infections and infestations - Other | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysphagia | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chills | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Oral pain | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dyspnea | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chills | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Infections and infestations - Other | Grade 3 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dyspnea | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chills | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Acute kidney injury | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dyspnea | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Catheter related infection | Not observed or Grade 1 | 7 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neutrophil count decreased | Grade 4 | 7 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dyspnea | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight loss | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Infections and infestations - Other | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dyspnea | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight loss | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Acute kidney injury | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Edema limbs | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight loss | Grade 2 | 2 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysphagia | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Edema limbs | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight gain | Not observed or Grade 1 | 4 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Infections and infestations - Other | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Edema limbs | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight gain | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Acute kidney injury | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Edema limbs | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight gain | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Nausea | Grade 2 | 4 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Edema limbs | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Infections and infestations - Other | Not observed or Grade 1 | 4 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Ejection fraction decreased | Grade 2 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Catheter related infection | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Acute kidney injury | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Ejection fraction decreased | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight gain | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neutrophil count decreased | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Ejection fraction decreased | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Catheter related infection | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Insomnia | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Ejection fraction decreased | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Weight gain | Grade 2 | 2 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Activated partial thromboplastin time prolonged | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Ejection fraction decreased | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Catheter related infection | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Activated partial thromboplastin time prolonged | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Vomiting | Not observed or Grade 1 | 4 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Insomnia | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Electrocardiogram QT corrected interval prolonged | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Vomiting | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Activated partial thromboplastin time prolonged | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Electrocardiogram QT corrected interval prolonged | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Catheter related infection | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Chills | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Vomiting | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Insomnia | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Electrocardiogram QT corrected interval prolonged | Not observed or Grade 1 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Cardiac troponin I increased | Not observed or Grade 1 | 7 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Activated partial thromboplastin time prolonged | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Epistaxis | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Cardiac troponin I increased | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Neutrophil count decreased | Not observed or Grade 1 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Epistaxis | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Vomiting | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Insomnia | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Epistaxis | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Cardiac troponin I increased | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Dysphagia | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Epistaxis | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Cardiac troponin I increased | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Activated partial thromboplastin time prolonged | Grade 2 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Epistaxis | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Vomiting | Grade 2 | 2 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Insomnia | Not observed or Grade 1 | 7 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fatigue | Grade 2 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sore throat | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory, thoracic and mediastinal disorders - Other | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fatigue | Grade 3 | 3 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sore throat | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Oral pain | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fatigue | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sore throat | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lung infection | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fatigue | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sore throat | Grade 3 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory, thoracic and mediastinal disorders - Other | Grade 3 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Fatigue | Not observed or Grade 1 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Sore throat | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Non-cardiac chest pain | Grade 2 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Febrile neutropenia | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Somnolence | Not observed or Grade 1 | 6 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Lung infection | Grade 3 | 2 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Febrile neutropenia | Grade 3 | 4 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Cardiac troponin I increased | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Respiratory, thoracic and mediastinal disorders - Other | Grade 2 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Febrile neutropenia | Grade 4 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Somnolence | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Abdominal pain | Not observed or Grade 1 | 1 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Febrile neutropenia | Grade 5 | 0 Participants |
| 2500 | Frequency of Toxicities Experienced by the Participants, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 | Somnolence | Grade 4 | 0 Participants |
Secondary
Overall Survival
Will use Kaplan-Meier estimation to analyze overall survival.
Time frame: Time from enrollment on trial to death from any cause, assessed up to 30 months after completion of therapy
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 1500 | Overall Survival | 5.4 months |
| 2000 | Overall Survival | 7.8 months |
| 2500 | Overall Survival | 10 months |
Secondary
Response Rate (CR and CRi), Assessed by Standard Criteria for AML
Confidence intervals will be calculated around the estimates of the response rate (CR and CRi). Assuming a response rate of 0.5, with 50 participants, 95 percent confidence intervals can be created with a 0.14 margin of error (0.36, 0.64).
Time frame: Up to 3 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 1500 | Response Rate (CR and CRi), Assessed by Standard Criteria for AML | 9 Participants |
| 2000 | Response Rate (CR and CRi), Assessed by Standard Criteria for AML | 7 Participants |
| 2500 | Response Rate (CR and CRi), Assessed by Standard Criteria for AML | 5 Participants |
Other Pre-specified
Complete Response
Complete response rates
Time frame: Up to 3 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 1500 | Complete Response | 8 Participants |
| 2000 | Complete Response | 5 Participants |
| 2500 | Complete Response | 2 Participants |
Other Pre-specified
Early Mortality (Death Within 60 Days of Beginning of Treatment)
Early mortality (death within 60 days of beginning of treatment).
Time frame: Up to 60 days
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 1500 | Early Mortality (Death Within 60 Days of Beginning of Treatment) | Alive at day 60 | 15 Participants |
| 1500 | Early Mortality (Death Within 60 Days of Beginning of Treatment) | Deceased at day 60 | 6 Participants |
| 2000 | Early Mortality (Death Within 60 Days of Beginning of Treatment) | Alive at day 60 | 14 Participants |
| 2000 | Early Mortality (Death Within 60 Days of Beginning of Treatment) | Deceased at day 60 | 6 Participants |
| 2500 | Early Mortality (Death Within 60 Days of Beginning of Treatment) | Alive at day 60 | 6 Participants |
| 2500 | Early Mortality (Death Within 60 Days of Beginning of Treatment) | Deceased at day 60 | 1 Participants |